Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Centruroides (scorpion) Immune F(ab')₂ Antivenin is a purified preparation of venom-specific immunoglobulin G F(ab')₂ fragments derived from the plasma of horses immunized with venom from several Centruroides species. It is administered intravenously for the treatment of clinical signs of envenomation following a sting by Centruroides genus scorpions. The drug works by passively introducing antibodies that bind to and neutralize circulating neurotoxins in the venom, thereby preventing them from interacting with their physiological targets and limiting systemic toxicity. This reduces or reverses symptoms such as loss of muscle control, abnormal eye movements, respiratory distress, excessive salivation, and vomiting. The product was developed in Mexico using pooled venoms from multiple Centruroides species and was approved by the FDA in 2011 under the brand name Anascorp[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on centruroides (scorpion) immune F(ab')₂ (equine).